Vivitrol does not require prior authorization for use.
Vivitrol is generally covered and does not require prior authorization for use.
Naltrexone for extended-release injectable suspension (Vivitrol) is an opioid antagonist. It is indicated for the:
- prevention of relapse to opioid dependence, following opioid detoxification, and
- treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment.
Opioid-dependent patients must be opioid-free at the time of initial Vivitrol administration. Patients should not be actively drinking at the time of initial administration. Vivitrol should be part of a comprehensive management program that includes psychosocial support.
If available, codes are listed below for informational purposes only, and do not guarantee member coverage or provider reimbursement. The list may not be all-inclusive.
J2315 – Injection, naltrexone, depot form, 1 mg
65757030001 – Vivitrol, 380 mg suspension, single use vialCPT Copyright American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.
- Alkermes. Vivitrol package insert. Waltham,MA. July 2013.
This information is for most, but not all, HealthPartners plans. Please read your plan documents to see if your plan has limits or will not cover some items. If there is a difference between this general information and your plan documents, your plan documents will be used to determine your coverage. These coverage criteria may not apply to Medicare Products if Medicare requires different coverage. For more information regarding Medicare coverage criteria or for a copy of a Medicare coverage policy, contact Member Services at 952-883-7979 or 1-800-233-9645.